Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Rangering i aksjer #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Aksjekurs
$0.5275
Markedsverdi
$1.25M
Endring (1 dag)
-3.56%
Endring (1 år)
-83.77%
Land
US
Handel Ensysce Biosciences, Inc. (ENSC)

Kategori

Healthcare
EPS for Ensysce Biosciences, Inc. (ENSC)
EPS per September 2025 TTM: $-6.37
Ifølge de siste økonomiske rapportene og aksjekursen til Ensysce Biosciences, Inc. er selskapets nåværende EPS (TTM) $-6.37. Ved slutten av 2023 hadde selskapet en EPS på $-4.69, en økning sammenlignet med EPS-en i 2022 som var $-139.44.
EPS-historikk for Ensysce Biosciences, Inc. fra 2017 til 2026
EPS ved slutten av hvert år
År EPS Endre
2026 (TTM) $-6.37 39.39%
2024 $-4.57 -2.56%
2023 $-4.69 -96.64%
2022 $-139.44 -60.80%
2021 $-355.68 -63,614.29%
2020 $0.56 133.33%
2019 $0.24 -209.09%
2018 $-0.22 4,130.77%
2017 $-0.01 0.00%
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $3.62 -156.86%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $15.47 -342.86%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $43.12 -776.92%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.62 -251.03%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $2.98 -146.78%
AU